<DOC>
	<DOCNO>NCT01021072</DOCNO>
	<brief_summary>The purpose study block interleukin-1 alpha activity True Human monoclonal antibody , thus interrupt inflammatory response support tumor growth/metastasis drive cachexic process . An adaptive design employ allow exploration different dosing regimen , well tumor type show preliminary evidence efficacy .</brief_summary>
	<brief_title>A First Man Study MABp1 Patients With Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>pathologically confirm advanced malignancy metastatic unresectable refractory standard therapy thee standard therapy provide benefit &gt; /= 3 month measurable nonmeasurable disease baseline least 4 week since last dose chemotherapy , radiation therapy , immunotherapy , surgery ; least 6 week therapy know delayed toxicity ; least 4 week since treatment biologic/targeted therapy ; least 2 week since last hormonal therapy treat chemotherapy , immunotherapy , radiotherapy investigational drug enrol protocol age &gt; /= 18 year , male female Eastern Cooperative Oncology Group performance status 0,1 , 2 Serum potassium magnesium level within institutional normal limit . Total serum calcium ionized calcium level must great equal low limit normal . Adequate renal function , define serum create &lt; /= 1.5 x ULN Adequate hepatic function Adequate bone marrow function WOCBP , negative serum pregnancy test result screening . WOCBP men whose sexual partner WOCBP willing use acceptable method contraception least 1 month prior study entry , duration study , least 3 month last dose study medication Signed dated IRB approve ICF protocol specific screening procedure perform serious uncontrolled medical disorder active infection would impair patient receive protocol therapy . Uncontrolled significant cardiovascular diseae dementia alter mental status would prohibit understanding rendering informed consent recover adverse effect prior therapy time enrollment &lt; /= grade 1 symptomatic brain metastasis either untreated uncontrolled surgery radiotherapy receive extensive prior radiation therapy bone marrow immunocompromised , include subject know infect HIV history hypersensitivity compound similar chemical biologic composition antibody woman pregnant breastfeed WOCBP men whose sexual partner WOCBP unwilling unable use acceptable method contraception least 1 month prior study entry , duration study , least 3 month last dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>